DLGAP5 Antibody

What is DLGAP5 and what are its primary functions in cellular processes?

DLGAP5 (Discs Large Homolog-Associated Protein 5) is a mitotic spindle protein that plays critical roles in cell cycle regulation. It belongs to the DLGAP protein family, which consists of 5 members (DLGAP1-5) distributed on different chromosomes. DLGAP5 promotes tubulin polymer formation at the ends of microtubules and is a target of cell cycle controllers and Aurora kinase A . Its depletion can lead to cycle prolongation and abnormal chromatin separation .

Key cellular functions of DLGAP5 include:

• Regulation of cell proliferation

• Modulation of cell migration and invasion

• Cell cycle control

• Tubulin polymerization at microtubule ends

• Chromosomal segregation during mitosis

In pathological conditions, particularly cancer, DLGAP5 is frequently upregulated and associated with poor prognosis in multiple cancer types including breast cancer, lung adenocarcinoma, and pancreatic cancer .

What are the key considerations when selecting a DLGAP5 antibody for research?

When selecting a DLGAP5 antibody, researchers should consider:

Epitope specificity: Available antibodies target different regions of DLGAP5 including:

• N-terminal region (AA 1-30)

• Central regions (AA 51-150, AA 228-258)

• C-terminal regions (AA 547-846)

Antibody format and validation:

• Verify whether the antibody has been validated for your specific application (WB, IHC, IF, FACS)

• Check whether validation data is available for your experimental system

• Review the clonality (most available DLGAP5 antibodies are polyclonal)

Reactivity spectrum:

• Human-specific vs. cross-reactive with mouse or other species

• Most commercial antibodies show reactivity to human DLGAP5, with some cross-reacting with mouse

Application compatibility:

• Western blotting antibodies typically work at dilutions that should be empirically determined

• Immunofluorescence applications may require different optimization parameters

• IHC applications may require specific fixation and retrieval conditions

How should I optimize Western blot conditions for DLGAP5 detection?

Sample preparation:

• For cell line analysis, RIPA buffer with protease inhibitors is recommended

• Based on published studies, DLGAP5 protein detection has been successfully performed in breast cancer cell lines (MDA-MB-231, MCF-7) and lung cancer cell lines

Gel and transfer conditions:

• Use 8-10% polyacrylamide gels as DLGAP5 has a molecular weight of ~100 kDa

• Transfer to PVDF membranes using standard wet transfer systems (1-2 hours at 100V)

Blocking and antibody incubation:

• Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary DLGAP5 antibodies at dilutions typically ranging from 1:500 to 1:2000

• Wash extensively (3-5 times) with TBST

• Incubate with appropriate HRP-conjugated secondary antibodies

Detection considerations:

• DLGAP5 expression varies significantly between cell lines, with MDA-MB-231 showing approximately four times higher expression than MCF-7 cells

• Include positive controls (e.g., HEK-293 cells have been validated for DLGAP5 antibody testing)

• Use appropriate loading controls (β-actin, GAPDH)

What are the recommended protocols for immunofluorescence detection of DLGAP5?

Cell preparation and fixation:

• Culture cells on glass coverslips to 50-70% confluence

• Fix with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.1-0.5% Triton X-100 for 10 minutes

Antibody incubation parameters:

• Block with 1-5% BSA or normal serum for 30-60 minutes

• Incubate with primary DLGAP5 antibody at dilutions typically ranging from 1:50 to 1:200

• Wash 3-5 times with PBS

• Incubate with fluorophore-conjugated secondary antibody

Nuclear counterstaining:

• DAPI is commonly used for nuclear counterstaining in DLGAP5 immunofluorescence studies

• This is particularly important since DLGAP5 has nuclear localization in many cell types

Validated cell lines:

• U2OS cells have been successfully used for DLGAP5 immunofluorescence studies

• Breast cancer and lung cancer cell lines also show detectable DLGAP5 expression

How can I effectively use DLGAP5 antibodies for flow cytometry analysis?

Sample preparation:

• Harvest cells using trypsin digestion

• Centrifuge and wash with PBS

• Fix with 4% paraformaldehyde or 70% ethanol (for cell cycle analysis)

• Permeabilize with 0.1% Triton X-100 for intracellular staining

Staining protocol:

• Block with 1-5% BSA in PBS

• Incubate with DLGAP5 antibody (suitable for FACS applications)

• Wash thoroughly with PBS

• Incubate with fluorophore-conjugated secondary antibody

• For apoptosis studies, co-stain with Annexin V-FITC and PI as demonstrated in DLGAP5 functional studies

Analysis considerations:

• DLGAP5 expression correlates with cell cycle phases (higher in G2/M)

• When analyzing DLGAP5 knockdown effects, consider cell cycle distribution changes

• For apoptosis analysis, follow protocols similar to those used in DLGAP5 functional studies using flow cytometry

How can I design DLGAP5 knockdown experiments to study its function in cancer cells?

siRNA design and selection:

• Based on published studies, multiple siRNA sequences have been validated for DLGAP5 knockdown

• In breast cancer studies, siRNA #2 and siRNA #3 interference sequences significantly reduced DLGAP5 expression at both gene and protein levels in MCF-7 and MDA-MB-231 cell lines

Transfection optimization:

• Lipid-based transfection methods have been successfully employed for DLGAP5 siRNA delivery

• Optimize cell density (typically 40-60% confluence at transfection)

• Verify knockdown efficiency by both qRT-PCR and Western blot

Functional assays following knockdown:

• Proliferation: CCK8 assays and colony formation assays have shown decreased proliferation ability in DLGAP5-silenced cells

• Migration: Wound-healing assays have demonstrated attenuated migratory potential with DLGAP5 knockdown

• Invasion: Transwell assays have shown reduced invasive potential in DLGAP5-silenced cells

• Cell cycle: Flow cytometry analysis should be performed to assess cell cycle distribution changes

Molecular analyses:

• Assess expression of proliferation-related genes (Ki67, Cyclin D1)

• Evaluate metastasis-related factors (E-cadherin, N-cadherin)

• Measure invasion factors (MMP2) which have been shown to be regulated by DLGAP5

What are the key considerations when studying DLGAP5 in various cancer types?

Breast cancer research:

• DLGAP5 is highly expressed in breast cancer tumor cells and associated with poor prognosis

• Primary expression is in malignant cells rather than fibroblast, endothelial, or epithelial cells

• Expression levels vary between breast cancer cell lines (e.g., higher in MDA-MB-231 than MCF-7)

• JAK/STAT pathway involvement has been demonstrated in DLGAP5 function in breast cancer

Lung adenocarcinoma (LUAD) research:

• DLGAP5 is upregulated in LUAD and correlates with unfavorable prognosis

• High DLGAP5 expression associates with mutation of major driver genes

• DLGAP5 relates to immune infiltration and elevated immune checkpoint blockade-related genes

• PLK1 has been identified as a downstream target of DLGAP5 in LUAD

• AT9283 has been identified as a potential DLGAP5 inhibitor that suppresses LUAD growth

Pancreatic cancer research:

• DLGAP5 has been investigated as a biomarker and potential therapeutic target

• Similar experimental approaches to breast and lung cancer studies can be applied

How can I investigate the relationship between DLGAP5 and signaling pathways in cancer?

JAK/STAT pathway analysis in breast cancer:

• KEGG enrichment analysis of DLGAP5 and related genes through the DAVID database revealed potential involvement in the JAK/STAT pathway

• Western blot and qRT-PCR can be used to detect JAK2/STAT3 pathway proteins and their relationship with DLGAP5

• Examine phosphorylation status of key pathway components

PLK1 pathway analysis in lung cancer:

• PLK1 has been identified as a downstream target of DLGAP5 in LUAD

• Overexpression or knockdown experiments should include PLK1 expression analysis

• Rescue experiments (PLK1 overexpression following DLGAP5 knockdown) can establish pathway dependencies

Experimental approaches:

• Co-immunoprecipitation to detect protein-protein interactions

• Chromatin immunoprecipitation to identify transcriptional regulation

• Pharmacological inhibitors of pathway components can help establish pathway hierarchies

• Phosphorylation-specific antibodies to monitor activation states of signaling proteins

How can I validate the specificity of my DLGAP5 antibody?

Positive controls:

• Use cell lines with known DLGAP5 expression (e.g., HEK-293, MDA-MB-231, U2OS)

• Include recombinant DLGAP5 protein as a standard in Western blots where available

Negative controls:

• DLGAP5 knockdown samples using validated siRNAs

• Cell lines with low endogenous expression (potentially MCF-7, which shows lower expression than MDA-MB-231)

Validation approaches:

• Peptide competition assays to confirm epitope specificity

• Use of multiple antibodies targeting different DLGAP5 epitopes

• Correlation of protein detection with mRNA expression data

• Molecular weight verification (~100 kDa for full-length DLGAP5)

What are the common pitfalls in DLGAP5 expression analysis and how to overcome them?

Tissue heterogeneity issues:

• DLGAP5 is primarily expressed in malignant cells rather than stromal components

• Single-cell RNA-seq has shown that DLGAP5 expression is predominantly in malignant cells marked by ERBB2 and BRCA1, not in fibroblasts, endothelial or epithelial cells

• For tissue samples, consider microdissection or single-cell approaches

Cell cycle dependency:

• DLGAP5 expression varies through the cell cycle, potentially confounding results

• Synchronize cells when possible for comparative studies

• Consider co-staining with cell cycle markers

Antibody selection issues:

• Different antibodies target distinct epitopes and may yield varying results

• Validate antibodies using multiple techniques (WB, IF, IHC)

• Consider post-translational modifications that might affect epitope accessibility

Expression level variations:

• DLGAP5 expression differs significantly between cell lines (e.g., 4x higher in MDA-MB-231 vs. MCF-7)

• Adjust exposure times and antibody concentrations accordingly

• Use appropriate positive controls calibrated to expected expression levels

How do experimental conditions affect DLGAP5 detection and functional analysis?

Fixation considerations for microscopy:

• Paraformaldehyde fixation (4%) is suitable for most immunofluorescence applications

• For immunohistochemistry, formalin-fixed paraffin-embedded sections require antigen retrieval methods

Buffer compositions for protein extraction:

• RIPA buffer with protease inhibitors is commonly used

• Phosphatase inhibitors should be included when studying signaling pathway interactions

Cell culture conditions influencing expression:

• Cell density can affect DLGAP5 expression (higher in proliferating vs. contact-inhibited cells)

• Serum starvation may alter expression due to cell cycle effects

• Consider synchronizing cells for comparative analysis

Functional assay optimization:

• For proliferation assays, CCK8 and colony formation have been successfully used

• Migration assays should be timed appropriately (24-48 hours for wound healing)

• Invasion assays using Transwell chambers may require optimization of cell numbers and matrix concentration

How should DLGAP5 expression data be quantified and statistically analyzed?

Western blot quantification:

• Normalization to housekeeping proteins (β-actin, GAPDH) is essential

• Densitometric analysis should use linear range exposures

• Multiple biological replicates (n=3 minimum) should be performed

• Statistical comparison using t-tests or ANOVA as appropriate

qRT-PCR data analysis:

• Use validated reference genes (18S has been used successfully in DLGAP5 studies)

• Apply the 2^-ΔΔCT method for relative quantification

• Consider baseline expression differences between cell types

Immunofluorescence quantification:

• Measure fluorescence intensity using appropriate imaging software

• Analyze sufficient cell numbers (>100 cells per condition)

• Consider subcellular localization patterns

• Use consistent exposure parameters between compared samples

Reporting standards:

• Present both representative images and quantitative data

• Include appropriate statistical tests and significance indicators

• Report antibody catalog numbers, dilutions, and validation methods

How can I integrate DLGAP5 antibody data with other molecular profiling approaches?

Correlation with transcriptomic data:

• Compare protein expression (by antibody) with mRNA levels (by qRT-PCR or RNA-seq)

• Bioinformatic analyses (differential analysis, weighted gene co-expression network analysis) have been used to identify DLGAP5 as a candidate gene in cancer studies

Integration with genomic data:

• DLGAP5 expression correlates with mutation of major driver genes in lung adenocarcinoma

• Databases like TCGA, GEO, CPTAC, and Human Protein Atlas can be used to explore correlations

Single-cell analysis approaches:

• scRNA-seq datasets (e.g., GSE176078) have been analyzed to clarify DLGAP5 localization in single cells

• Cell annotation using marker genes helps identify cell types expressing DLGAP5

Pathway analysis integration:

• KEGG enrichment analysis through the DAVID database has revealed pathway connections

• Network pharmacology approaches have been used to screen potential DLGAP5 inhibitors

• These computational approaches should be validated with antibody-based experimental evidence